International Journal for Parasitology-Drugs and Drug Resistance

Scope & Guideline

Elevating the Discourse on Parasitology and Therapeutics

Introduction

Immerse yourself in the scholarly insights of International Journal for Parasitology-Drugs and Drug Resistance with our comprehensive guidelines detailing its aims and scope. This page is your resource for understanding the journal's thematic priorities. Stay abreast of trending topics currently drawing significant attention and explore declining topics for a full picture of evolving interests. Our selection of highly cited topics and recent high-impact papers is curated within these guidelines to enhance your research impact.
LanguageEnglish
ISSN2211-3207
PublisherELSEVIER SCI LTD
Support Open AccessYes
CountryNetherlands
TypeJournal
Convergefrom 2011 to 2024
AbbreviationINT J PARASITOL-DRUG / Int. J. Parasitol.-Drugs Drug Resist.
Frequency3 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address125 London Wall, London EC2Y 5AS, ENGLAND

Aims and Scopes

The International Journal for Parasitology-Drugs and Drug Resistance focuses on advancing the understanding of parasitic diseases through innovative drug development and resistance studies. The journal emphasizes research that explores the mechanisms of drug action and resistance, aiming to provide insights that can lead to more effective treatments for parasitic infections.
  1. Drug Discovery and Development:
    The journal prioritizes research on the discovery and development of new drugs targeting various parasites, including protozoa, helminths, and ectoparasites, utilizing both traditional and novel methodologies.
  2. Mechanisms of Drug Resistance:
    A significant focus is placed on understanding the mechanisms behind drug resistance in parasitic organisms, which is crucial for developing strategies to combat resistance.
  3. Therapeutic Strategies and Innovations:
    The journal covers innovative therapeutic strategies, including the repurposing of existing drugs, combination therapies, and the use of natural products as potential treatments for parasitic infections.
  4. In Vitro and In Vivo Studies:
    Research involving both in vitro and in vivo studies is emphasized, providing comprehensive insights into the efficacy and safety of new treatments against various parasitic diseases.
  5. Epidemiology of Parasitic Infections:
    The journal also addresses the epidemiological aspects of parasitic infections, particularly the spread and impact of drug resistance in different geographical regions.
Recent publications in the journal reveal several emerging themes that reflect the evolving landscape of parasitology research, particularly in drug discovery and resistance mechanisms. These trends indicate a growing urgency to address the challenges posed by parasitic diseases.
  1. High-Throughput Screening Techniques:
    There is an increasing trend towards utilizing high-throughput screening methods for drug discovery, enabling rapid identification of potential antiparasitic compounds.
  2. Natural Products as Antiparasitic Agents:
    Research exploring the antiprotozoal and anthelmintic properties of natural products has gained momentum, highlighting the potential of traditional medicine and biodiversity in drug discovery.
  3. Genetic and Genomic Approaches:
    Emerging themes include the use of genetic and genomic tools to understand drug resistance mechanisms at a molecular level, facilitating targeted drug development.
  4. Combination Therapies:
    The exploration of combination therapies to enhance efficacy and reduce the likelihood of resistance is increasingly prominent, reflecting a strategic shift in treatment paradigms.
  5. Environmental and Epidemiological Studies:
    There is a growing emphasis on the environmental and epidemiological factors influencing the spread of drug resistance, which is critical for devising effective control strategies.

Declining or Waning

While the journal remains at the forefront of parasitology research, certain themes appear to be declining in frequency or prominence. This may reflect shifts in research focus or advancements in understanding that have led to saturation in specific areas.
  1. Traditional Antiparasitic Agents:
    There seems to be a waning focus on traditional antiparasitic agents, as newer classes of drugs and innovative treatment strategies gain prominence, reflecting a shift towards more effective and targeted therapies.
  2. Basic Biochemical Pathways of Parasites:
    Research concentrated solely on the basic biochemical pathways of parasites without direct implications for drug development appears to be declining, as studies increasingly aim for translational applications.
  3. Efficacy Testing of Established Treatments:
    The frequency of studies solely evaluating the efficacy of well-established treatments without exploring new alternatives or combination therapies has decreased, indicating a shift towards more novel investigational approaches.

Similar Journals

EXPERT OPINION ON THERAPEUTIC TARGETS

Unveiling the mechanisms that drive therapeutic breakthroughs.
Publisher: TAYLOR & FRANCIS LTDISSN: 1472-8222Frequency: 12 issues/year

Expert Opinion on Therapeutic Targets, published by Taylor & Francis Ltd, is a highly respected journal in the fields of Clinical Biochemistry, Drug Discovery, Molecular Medicine, and Pharmacology. With a focus on cutting-edge research and innovative approaches to therapeutic development, this journal has established itself as a leading platform for scholars and practitioners, boasting a prestigious Q1 ranking across multiple categories in 2023. The journal aims to present expert perspectives on novel therapeutic strategies, promising drug candidates, and insights into the intricate mechanisms underlying various diseases. Its impressive impact factor reflects the journal's commitment to advancing scientific knowledge and influencing clinical practice. With its inception in 1997 and ongoing publication through to 2024, Expert Opinion on Therapeutic Targets continues to be an invaluable resource for those seeking to stay at the forefront of therapeutic innovations.

DRUG METABOLISM AND DISPOSITION

Fostering Excellence in Pharmacology and Toxicology
Publisher: AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICSISSN: 0090-9556Frequency: 12 issues/year

Drug Metabolism and Disposition is a premier journal published by the American Society for Pharmacology and Experimental Therapeutics, focusing on crucial advancements in the fields of pharmaceutical sciences and pharmacology. Since its inception in 1973, this esteemed journal has established itself as a leading platform for innovative research, earning a prestigious Q1 rating in both Pharmaceutical Science and Pharmacology categories as of 2023. With an impressive Scopus ranking of #52 out of 183 in Pharmaceutical Science and #105 out of 313 in Pharmacology, it occupies a vital place in an increasingly competitive academic landscape. Researchers, professionals, and students alike benefit from its rigorous peer-reviewed articles that delve into drug metabolism processes and their physiological implications, making it an indispensable resource for anyone aiming to advance their understanding of drug disposition and efficacy. This crucial journal contributes significantly to the ongoing dialogue in pharmacology and toxicology, providing insights that help shape future therapeutic strategies and regulatory policies.

DRUG DEVELOPMENT RESEARCH

Pioneering insights in pharmacology and toxicology.
Publisher: WILEYISSN: 0272-4391Frequency: 8 issues/year

DRUG DEVELOPMENT RESEARCH is a premier interdisciplinary journal published by Wiley, focusing on the latest advancements in drug discovery, pharmacology, and toxicology. With an ISSN of 0272-4391 and an E-ISSN of 1098-2299, this esteemed publication has been a cornerstone in the field since its inception in 1981 and continues to provide cutting-edge research until 2024. Its rigorous peer-review process and strategic placement in Q2 of the Drug Discovery category, as well as ranking #60 out of 157 in Scopus, underscore the journal's relevance and influence, boasting a respectable 62nd percentile ranking. While the journal does not currently offer open access, it remains a vital resource for researchers, professionals, and students seeking to expand their knowledge on the processes of drug development, identifying new therapeutic targets, and assessing the efficacy and safety of novel compounds. Situated in Hoboken, NJ, this journal stands at the forefront of pharmaceutical innovation, making significant contributions to the advancement of medical science.

PARASITOLOGY RESEARCH

Elevating understanding through rigorous research and review.
Publisher: SPRINGERISSN: 0932-0113Frequency: 12 issues/year

PARASITOLOGY RESEARCH, published by Springer, stands as a pivotal journal in the fields of parasitology, infectious diseases, and insect science, with a rich history dating back to 1987. Operating from Germany, this journal has garnered an impressive reputation, achieving a high ranking within various categories, including Q1 in Veterinary (miscellaneous) and Q2 across several relevant fields as of 2023. While it does not currently offer Open Access options, the journal remains a vital resource for researchers, professionals, and students seeking to contribute to and keep pace with advancements in parasitological studies. With a commitment to publishing high-quality research, PARASITOLOGY RESEARCH serves as an essential forum for disseminating findings that enhance our understanding of parasitic organisms and their impacts on health and the environment. Explore this journal to engage with cutting-edge investigations and reviews that drive innovation in parasitology and related disciplines.

Drug Discoveries and Therapeutics

Unveiling the future of drug development and therapy.
Publisher: INT RESEARCH & COOPERATION ASSOC BIO & SOCIO-SCIENCES ADVANCEMENTISSN: 1881-7831Frequency: 6 issues/year

Drug Discoveries and Therapeutics is a highly regarded journal devoted to the advancement of knowledge in the field of medicine and pharmacology. Published by the International Research & Cooperation Association for Biological & Socio-Sciences Advancement in Tokyo, Japan, this journal serves as a vital resource for researchers, practitioners, and students interested in the latest developments in drug discovery and therapeutic strategies. With a Scopus ranking of #192 out of 826 in the General Medicine category, and positioning itself in the 76th percentile, it demonstrates a significant impact within the scientific community. The journal publishes original research articles, reviews, and innovative studies that address the complexities of drug development, therapeutic efficacy, and clinical applications. Researchers and clinicians can access valuable insights to enhance their practices and inform further studies as it continues to disseminate crucial findings essential for the advancement of medical science.

Expert Opinion on Drug Discovery

Connecting Experts in Drug Development
Publisher: TAYLOR & FRANCIS LTDISSN: 1746-0441Frequency: 6 issues/year

Expert Opinion on Drug Discovery, published by Taylor & Francis Ltd, is a premier journal dedicated to the rapidly evolving field of drug development and innovation. With a strong emphasis on the integration of multidisciplinary approaches in pharmacology and toxicology, the journal has established itself as an invaluable resource for researchers, professionals, and students alike. Its impressive impact factor and classification as a Q1 journal in drug discovery, alongside its high Scopus ranking (Rank #20/157, Percentile 87th), underscore its significance within the academic community. Spanning from 2006 to 2024, Expert Opinion on Drug Discovery features a wide range of expert reviews and opinion articles that provide insights into the latest trends and breakthroughs in drug discovery, fostering collaboration and knowledge exchange. While the journal is not open access, it plays a critical role in shaping the future of drug development, making it an essential platform for those seeking to deepen their understanding of this dynamic field.

ARCHIVES OF PHARMACAL RESEARCH

Advancing pharmaceutical knowledge through innovative research.
Publisher: PHARMACEUTICAL SOC KOREAISSN: 0253-6269Frequency: 12 issues/year

Archives of Pharmacal Research, published by the Pharmaceutical Society of Korea, is a leading journal in the fields of drug discovery, molecular medicine, and organic chemistry. With an illustrious history spanning from 1978 to 2024, this peer-reviewed journal has earned a remarkable reputation, achieving a Q1 category ranking in each of its primary research areas as of 2023. Ranked #9 in Organic Chemistry and #12 in Drug Discovery among their respective fields, Archives of Pharmacal Research showcases cutting-edge research that contributes significantly to scientific advancements. Although it is not an open-access journal, its impactful publications are crucial resources for researchers, professionals, and students navigating the complexities of pharmacological sciences. The journal's continued commitment to disseminating high-quality research underlines its importance in fostering innovation and expanding knowledge within the pharmaceutical landscape.

ANTI-CANCER DRUGS

Pioneering Discoveries in Oncology Pharmacology
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 0959-4973Frequency: 10 issues/year

ANTI-CANCER DRUGS is a leading journal in the domain of cancer research and pharmacology, published by Lippincott Williams & Wilkins. With its inception dating back to 1990 and ongoing publication through 2024, this journal serves as a vital resource for researchers, clinicians, and students interested in the latest advancements and discoveries in cancer therapeutics. Although classified in the Q3 quartile across relevant categories such as Cancer Research and Oncology, its growing impact is evidenced by its competitive Scopus rankings, positioned within the 30th to 52nd percentiles across various disciplines. The journal remains committed to promoting innovative research that can translate into effective anti-cancer strategies, providing valuable insights into drug development and applications. While it does not currently offer open access, the journal continues to attract a sophisticated readership, making it an essential platform for disseminating significant findings in the ever-evolving field of oncology.

Parasitologists United Journal

Uniting Expertise for a Healthier Tomorrow
Publisher: Egyptian Parasitologists United Soc - EPUISSN: 1687-7942Frequency: 3 issues/year

Parasitologists United Journal is a premier academic outlet dedicated to advancing the field of parasitology. Published by the Egyptian Parasitologists United Society (EPU), this journal serves as a critical platform for researchers, professionals, and students alike, allowing them to share innovative findings and developments in the study of parasites and their impacts on human, animal, and environmental health. With an ISSN of 1687-7942 and an E-ISSN of 2090-2646, it aims to promote knowledge dissemination while fostering collaboration across borders. Although currently not an Open Access journal, its commitment to high-quality, peer-reviewed content ensures that the latest research reaches discerning readers. By featuring a diverse array of articles spanning various aspects of parasitology, the journal significantly contributes to the global understanding of parasitic diseases and their management, making it an essential resource for academic and clinical professionals seeking to enhance their expertise in this vital area of health science.

Future Medicinal Chemistry

Exploring innovative solutions in medicinal chemistry.
Publisher: Newlands Press LtdISSN: 1756-8919Frequency: 24 issues/year

Future Medicinal Chemistry is a premier journal dedicated to the rapidly evolving fields of drug discovery, pharmacology, and molecular medicine. Published by Newlands Press Ltd in the United Kingdom, this journal has garnered significant attention within the academic community, evidenced by its 2023 category rankings in Scopus, placing it in the Q2 quartile for Drug Discovery and the Q3 quartiles for both Molecular Medicine and Pharmacology. With an ISSN of 1756-8919 and an E-ISSN of 1756-8927, Future Medicinal Chemistry has been a cornerstone of scholarly discourse since its inception in 2009, continuously contributing to the advancement of knowledge and discussion in medicinal chemistry. The journal is committed to publishing high-quality, peer-reviewed research that addresses the challenges and innovations in drug development and therapeutic strategies, making it an essential resource for researchers, professionals, and students seeking to stay at the forefront of these critical fields. Engage with the latest findings and methodologies that shape the future of medicine by exploring the wealth of information offered within Future Medicinal Chemistry.